Matthew Vincent Dolan, EVP Strategy & Corporate Development at DEXCOM INC (DXCM), sold 8,406 shares at $130.77 ($1.1M) on 2024-03-15, disclosed to the SEC on 2024-03-19.
Scheduled sale ($1.1M) by EVP Strategy & Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $129.18 | 1,886 | $244K | 22.3% |
| 2 | $129.18 | 1,886 | $244K | 22.3% |
| 3 | $130.77 | 1,314 | $172K | 15.7% |
| 4 | $130.77 | 1,314 | $172K | 15.7% |
| 5 | $131.39 | 1,003 | $132K | 12.0% |
| 6 | $131.39 | 1,003 |
| $132K |
| 12.0% |
| Total | $130.20 avg | 8,406 | $1.1M | 100% |
| Filing → |
| DXCM | SELL | 2024-04-16 | $548K | — | Filing → |
| DXCM | SELL | 2024-03-14 | $1.8M | — | Filing → |
| DXCM | SELL | 2023-09-01 | $6K | — | Filing → |